Market research
MDWD Mediwound Ltd
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 171M
- P/E ratio
- Not available
- Analyst target
- 29.8333
- Dividend yield
- Not available
- Beta
- 0.16
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- IL0011316309
- Market cap
- 171M
- P/E ratio
- Not available
- Analyst target
- 29.8333
- Dividend yield
- Not available
- Beta
- 0.16
About
About Mediwound Ltd
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. It also develops EscharEx, a bromelain-based, bioactive enzymatic therapy for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the MDWD discussion.
5 years, 4 months ago
MediWound Ltd is currently in a long term downtrend where the price is trading 1.9% below its 200 day moving average.
From a valuation standpoint, the stock is 99.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 6.7.
MediWound Ltd's total revenue rose by 22.6% to $7M since the same quarter in the previous year.
Its net income has increased by 49.7% to $-2M since the same quarter in the previous year.
Finally, its free cash flow fell by 43.3% to $-4M since the same quarter in the previous year.
Based on the above factors, MediWound Ltd gets an overall score of 3/5.